- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00083993
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment. The primary endpoint of this study is to determine overall progression free survival.
Individual subjects will participate in the active treatment phase of the study until disease progression or withdrawal of consent, provided that test article is being tolerated. All subjects will be asked to participate in the long-term follow-up phase of the study, which includes follow-up every 3 months until disease progression (for subjects who withdraw for reasons other than documented progressive disease) or until any new cancer treatment is received, and for survival. The estimated duration of study participation is 34 months.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N2
-
-
British Columbia
-
North Vancouver, British Columbia, Canada, V7L 2L7
-
Richmond, British Columbia, Canada, V6X1A2
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
-
Hamilton, Ontario, Canada, L8V 5C2
-
Newmarket, Ontario, Canada, L3Y 2P9
-
Toronto, Ontario, Canada, M5G 2M9
-
Toronto, Ontario, Canada, M5G 1X5
-
Toronto, Ontario, Canada, M4C-3E7
-
Toronto, Ontario, Canada, M4N 3N5
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 5H6
-
Fleurimont, Quebec, Canada, J1H 5N4
-
Levis, Quebec, Canada, G1V3Z1
-
Pointe Claire, Quebec, Canada, H9R4S3
-
Quebec City, Quebec, Canada, G1R2J6
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N4H4
-
-
-
-
Alabama
-
Hoover, Alabama, Forente stater, 35216
-
Huntsville, Alabama, Forente stater, 35801
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85715
-
-
Arkansas
-
Jonesboro, Arkansas, Forente stater, 72401
-
-
California
-
Burbank, California, Forente stater, 91505
-
Campbell, California, Forente stater, 95008
-
Fountain Valley, California, Forente stater, 92708
-
Gilroy, California, Forente stater, 95020
-
Glendora, California, Forente stater, 91740
-
Modesto, California, Forente stater, 95355
-
Montebello, California, Forente stater, 90640
-
Pomona, California, Forente stater, 91767
-
Poway, California, Forente stater, 92064
-
Sacramento, California, Forente stater, 95816
-
San Diego, California, Forente stater, 92123
-
Santa Rosa, California, Forente stater, 95405
-
Soquel, California, Forente stater, 95073
-
Vista, California, Forente stater, 92083
-
-
Colorado
-
Lakewood, Colorado, Forente stater, 80215
-
-
Connecticut
-
Norwalk, Connecticut, Forente stater, 06851
-
-
District of Columbia
-
Washington, District of Columbia, Forente stater, 20010
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33428
-
Fort Lauderdale, Florida, Forente stater, 33305
-
Hollywood, Florida, Forente stater, 33021
-
Jacksonville, Florida, Forente stater, 32209
-
Jacksonville, Florida, Forente stater, 32224
-
Lake Worth, Florida, Forente stater, 33461
-
Miami Shores, Florida, Forente stater, 33138
-
New Port Richey, Florida, Forente stater, 34652
-
Plantation, Florida, Forente stater, 33324
-
Sarasota, Florida, Forente stater, 34239
-
Zephyrhills, Florida, Forente stater, 33542
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30309-1710
-
Columbus, Georgia, Forente stater, 31902
-
Roswell, Georgia, Forente stater, 30076
-
Thomasville, Georgia, Forente stater, 31792
-
-
Idaho
-
Coeur d'Alene, Idaho, Forente stater, 83814
-
-
Illinois
-
Centralia, Illinois, Forente stater, 62801
-
Skokie, Illinois, Forente stater, 60076
-
Skokie, Illinois, Forente stater, 60077
-
Springfield, Illinois, Forente stater, 62702
-
Urbana, Illinois, Forente stater, 61801
-
-
Indiana
-
Munster, Indiana, Forente stater, 46321
-
South Bend, Indiana, Forente stater, 46601
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40504
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
-
Baltimore, Maryland, Forente stater, 21237
-
Baltimore, Maryland, Forente stater, 21231
-
Bethesda, Maryland, Forente stater, 20817
-
Frederick, Maryland, Forente stater, 21701
-
Towson, Maryland, Forente stater, 21204
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02135
-
Boston, Massachusetts, Forente stater, 02118
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
-
Detroit, Michigan, Forente stater, 48202
-
Flint, Michigan, Forente stater, 48503
-
Grand Rapids, Michigan, Forente stater, 49503
-
Grand Rapids, Michigan, Forente stater, 49546
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
-
-
Mississippi
-
Hattiesburg, Mississippi, Forente stater, 39401
-
-
Missouri
-
Rolla, Missouri, Forente stater, 65401
-
-
Montana
-
Great Falls, Montana, Forente stater, 59406
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68198
-
-
Nevada
-
Carson City, Nevada, Forente stater, 89703
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
-
-
New Jersey
-
Belleville, New Jersey, Forente stater, 07109
-
Somerset, New Jersey, Forente stater, 08873
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
-
-
New York
-
Binghamton, New York, Forente stater, 13905
-
East Syracuse, New York, Forente stater, 13057
-
New York, New York, Forente stater, 10032
-
Nyack, New York, Forente stater, 10960
-
Staten Island, New York, Forente stater, 10305
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28203
-
Gastonia, North Carolina, Forente stater, 28054
-
Wilmington, North Carolina, Forente stater, 28401
-
Winston-Salem, North Carolina, Forente stater, 27103
-
-
North Dakota
-
Bismark, North Dakota, Forente stater, 58504
-
-
Ohio
-
Canton, Ohio, Forente stater, 44718
-
Canton, Ohio, Forente stater, 44710
-
Cincinnati, Ohio, Forente stater, 45219
-
Cincinnati, Ohio, Forente stater, 45238
-
Cleveland, Ohio, Forente stater, 44195
-
Cleveland, Ohio, Forente stater, 44106-5055
-
Columbus, Ohio, Forente stater, 43215
-
Columbus, Ohio, Forente stater, 43235
-
Mayfield Heights, Ohio, Forente stater, 44124
-
-
Oregon
-
Corvallis, Oregon, Forente stater, 97330
-
Portland, Oregon, Forente stater, 97213
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, Forente stater, 17110
-
Hershey, Pennsylvania, Forente stater, 17033
-
Langhorne, Pennsylvania, Forente stater, 19047
-
Philadelphia, Pennsylvania, Forente stater, 19106
-
Pittsburgh, Pennsylvania, Forente stater, 15213
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
-
Columbia, South Carolina, Forente stater, 29169
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
-
Nashville, Tennessee, Forente stater, 37203
-
Nashville, Tennessee, Forente stater, 37205
-
-
Texas
-
Arlington, Texas, Forente stater, 76012
-
Corpus Christi, Texas, Forente stater, 78412
-
Dallas, Texas, Forente stater, 75230
-
Fort Worth, Texas, Forente stater, 76104
-
Irving, Texas, Forente stater, 75038
-
Tyler, Texas, Forente stater, 75701
-
-
Utah
-
Logan, Utah, Forente stater, 84341
-
Ogden, Utah, Forente stater, 84403
-
-
Virginia
-
Arlington, Virginia, Forente stater, 22205-3637
-
Richmond, Virginia, Forente stater, 23294
-
Woodbridge, Virginia, Forente stater, 22191
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26505
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women aged greater than 18 years.
- Postmenopausal subjects
- Confirmed diagnosis of locally advanced (not amenable to curative surgery and/or radiation) or metastatic breast cancer (Stage 3B or 4 respectively, by American Joint Committee on Cancer Criteria)
Exclusion Criteria:
- Extensive visceral disease
- Subjects with bone as the only site of disease
- Prior radiation therapy to the site of measurable disease for subjects with a solitary measurable lesion
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
|---|
|
To determine overall progression free survival.
|
Sekundære resultatmål
Resultatmål |
|---|
|
To determine safety, survival, health outcomes, prognostic markers and pharmacogenomics analysis.
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Hudsykdommer
- Neoplasmer etter nettsted
- Bryst sykdommer
- Neoplastiske prosesser
- Neoplasmer
- Brystneoplasmer
- Neoplasma Metastase
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Enzymhemmere
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Hormoner, hormonsubstitutter og hormonantagonister
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Hormonantagonister
- Antifungale midler
- Aromatasehemmere
- Steroidesyntesehemmere
- Østrogenantagonister
- Letrozol
- Sirolimus
Andre studie-ID-numre
- 3066A1-303
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .